Resources from the same session
My preferred choice is PD-1 monotherapy, and these are the reasons why
Presenter: Teresa Petrella
Session: First-line therapy in advanced melanoma: What is my preferred choice?
Resources:
Slides
Webcast
My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why
Presenter: Ana Maria Arance Fernandez
Session: First-line therapy in advanced melanoma: What is my preferred choice?
Resources:
Slides
Webcast
I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why
Presenter: Reinhard Dummer
Session: First-line therapy in advanced melanoma: What is my preferred choice?
Resources:
Slides
Webcast